Skip to main content

Advertisement

Table 2 Shantha's Product Pipeline (2009)

From: Indian vaccine innovation: the case of Shantha Biotechnics

Product Description Development Stage Development Partners
Vaccines   
Hepatitis B (Shanvac-B) On market since 1997, post-marketing survey in progress CCMB (India)
Japanese Encephalitis (Jencevac) On market Green Cross Vaccine Corporation (Korea)
Hib (ShanHib) On market Berna Biotech (Switzerland)
Rotavirus Preclinical NIH, Bill and Melinda Gates Foundation, PATH
Varicella Preclinical NIH
Dengue Preclinical Inviragen, CDC
HPV Preclinical NIH, NCI, John's Hopkins University
Pneumococcal R&D PATH
Meningococcal A (Intervax) On market Intervax Biologics (Canada)
Meningococcal C (Intervax) On market Intervax Biologics (Canada)
Cholera (oral) Clinical trials International Vaccine Institute, Korea
Typhoid Clinical trials International Vaccine Institute, Korea
Combination Vaccines   
MMR R&D -
DPT On market -
Shantetra: DPT, Hep B On market -
ShanHib-DPT: Hib, DPT On market -
Shan5: DPT, Hep B, Hib On market -
DPT, Hep B, influenza Was expected on market 2009 -
Monoclonal Antibodies   
Lung cancer Preclinical -
Melanoma Preclinical -
Cocktail R&D -
Bio-therapeutics   
Interferon α 2b (Shanferon) On market -
Erythropoietin (Shanpoietin) On market (launched 2005) -
Streptokinase (Shankinase) On market - discontinued -
Insulin On market Biocon
GCSF Clinical trials -
Diagnostics   
Hepatitis B On market -
Cancer (α-feto protein) On market -